Hematopoietic stem cell expansion and gene therapy

References

• Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, . Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990;323:570–8.
   PubMed Web of Science ®Google Scholar
• Blaese RM, Culver KW, Miller AD, Carter CS, Clerici M, Shearer G, . T lymphocyte-directed gene therapy for ADA-SCID; initial trial results after 4 years. Science. 1995; 270:475–80.
   PubMed Web of Science ®Google Scholar
• Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, . Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12: 401–9.
   PubMed Web of Science ®Google Scholar
• Ferrua F, Brigida I, Aiuti A. Review. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Curr Op Allergy Clin Immunol. 2010;10:551–6.
   Google Scholar
• Lee B, Davidson BL. Gene therapy grows into young adulthood: special review issue. Hum Mol Genet. 2011;20:R1.
   PubMedGoogle Scholar
• Denefle PP. Introduction to gene therapy: a clinical aftermath. Meth Mol Biology. 2011;737:27–44.
   Google Scholar
• Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, Sutton SE, . Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010;329:1345–8.
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, . Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669–72.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, . Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2010;363: 355–64.
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, . Transfusion independence and HMGA2 activation after gene therapy of human-thalassaemia. Nature. 2010;467:318–22.
   PubMed Web of Science ®Google Scholar
• Roselli EA, Mezzadra R, Frittoli MC, Maruggi G, Biral E, Mavilio F, . Correction of beta-thalassemia major by gene transfer in haematopoietic progenitors of pediatric patients. EMBO Mol Med. 2010;2:315–28.
   PubMed Web of Science ®Google Scholar
• Naldini L. Review. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet. 2011;12:301–15.
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, . Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118:3132–42.
   PubMed Web of Science ®Google Scholar
• Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, . Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med. 2010; 16:198–204.
   PubMed Web of Science ®Google Scholar
• Notarangelo LD. Review. Primary immunodeficiencies. J Allergy Clin Immunol. 2010;125:S182–94.
   PubMed Web of Science ®Google Scholar
• Aiuti A, Roncarolo MG. Review. Ten years of gene therapy for primary immune deficiencies. Hematology. 2009;682–9.
   Google Scholar
• Fischer A, Hacein-Bey-Abina S, Cavazzana-Calvo M. 20 years of gene therapy for SCID. Nat Immunol. 2010;11:457–60.
   PubMed Web of Science ®Google Scholar
• Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, . Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410–3.
   PubMed Web of Science ®Google Scholar
• Liu JM, Kim S, Read EJ, Futaki M, Dokal I, Carter CS, . Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). Hum Gene Ther. 1999;10:2337–46.
   PubMed Web of Science ®Google Scholar
• Sidransky E, LaMarca ME, Ginns EI. Review. Therapy for Gaucher disease: don't stop thinking about tomorrow. Mol Gen Metab. 2007;90:122–5.
   Google Scholar
• Bolling T, Kreuziger DC, Ernst I, Elsayed H, Willich N. Retrospective, monocentric analysis of late effects after total body irradiation (TBI) in adults. Strahlenther Onkol. 2011; 187:311–5.
   Google Scholar
• Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, . Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant. 2002;8:368–76.
   PubMed Web of Science ®Google Scholar
• de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, . Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant. 2008; 41:771–8.
   PubMed Web of Science ®Google Scholar
• Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010;16:232–7.
   PubMed Web of Science ®Google Scholar
• Zhang CC, Kaba M, Iizuka S, Huynh H, Lodish HF. Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation. Blood. 2008;111:3415–23.
   PubMed Web of Science ®Google Scholar
• Oike Y, Yasunaga K, Suda T. Review. Angiopoietin-related/angiopoietin-like proteins regulate angiogenesis. Int J Hematol. 2004;80:21–8.
   PubMed Web of Science ®Google Scholar
• Ranke MB, Elmlinger M. Review. Functional role of insulin-like growth factor binding proteins. Horm Res. 1997; 48(Suppl 4):9–15.
   Google Scholar
• Prus E, Fibach E. The effect of the copper chelator tetraethylenepentamine on reactive oxygen species generation by human hematopoietic progenitor cells. Stem Cells Develop. 2007;16:1053–6.
   PubMed Web of Science ®Google Scholar
• Delaney C, Varnum-Finney B, Aoyama K, Brashem-Stein C, Bernstein ID. Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. Blood. 2005;106:2693–9.
   PubMed Web of Science ®Google Scholar
• McNiece I, Harrington J, Turney J, Kellner J, Shpall EJ. Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. Cytotherapy. 2004;6:311–7.
   PubMed Web of Science ®Google Scholar
• Robinson SN, Simmons PJ, Yang H, Alousi AM, Marcos DL, Shpall EJ. Review. Mesenchymal stem cells in ex vivo cord blood expansion. Bailliere's Best Prac Clin Haematol. 2011;24:83–92.
   PubMed Web of Science ®Google Scholar
• Zhang X-B, Beard BC, Beebe K, Storer B, Humphries RK, Kiem H-P. Differential effects of HOXB4 on nonhuman primate short- and long-term repopulating cells. PLoS Med. 2006;3:687–698.
   Google Scholar
• Krosl J, Austin P, Beslu N, Kroon E, Humphries RK, Sauvageau G. In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein. Nat Med. 2003;9: 1428–32.
   PubMed Web of Science ®Google Scholar
• Watts KL, Delaney C, Humphries RK, Bernstein I, Kiem H-P. Combination of HOXB4 and delta-1 ligand improves expansion of cord blood cells. Blood. 2010;116:5859–66.
   Google Scholar
• Horn PA, Thomasson BM, Wood BL, Andrews RG, Morris JC, Kiem H-P. Distinct hematopoietic stem/progenitor cell populations are responsible for repopulating NOD/SCID mice compared with nonhuman primates. Blood. 2003;102: 4329–35.
   PubMed Web of Science ®Google Scholar
• Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, . Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174:6477–89.
   PubMed Web of Science ®Google Scholar
• Piacibello W, Bruno S, Sanavio F, Droetto S, Gunetti M, Ailles L, . Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient. Blood. 2002;100:4391–400.
   PubMed Web of Science ®Google Scholar
• Tisdale JF, Hanazono Y, Sellers SE, Agricola BA, Metzger ME, Donahue RE, . Ex vivo expansion of genetically marked Rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood. 1998; 92:1131–41.
   PubMed Web of Science ®Google Scholar
• Guy K, Middleton PG, Bansal NS, Ross JA, Steel CM. Recurrent mutation of immunoglobulin and c-myc genes and differential expression of cell surface antigens occur in variant cell lines derived from a Burkitt lymphoma. Int J Cancer. 1990;45:109–18.
   PubMed Web of Science ®Google Scholar
• Zhang X-B, Beard BC, Trobridge GD, Wood BL, Sale GE, Sud R, . High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. J Clin Invest. 2008;118:1502–10.
   PubMed Web of Science ®Google Scholar
• Li X, Le Beau MM, Ciccone S, Yang FC, Freie B, Chen S, . Ex vivo culture of Fancc–/– stem/progenitor cells predisposes cells to undergo apoptosis, and surviving stem/ progenitor cells display cytogenetic abnormalities and an increased risk of malignancy. Blood. 2005;105:3465–71.
   Google Scholar
• Micklem HS, Clarke CM, Evans EP, Ford CE. Fate of chromosome-marked mouse bone marrow cells transfused into normal syngeneic recipients. Transplantation. 1968;6: 299–302.
   PubMedGoogle Scholar
• Brecher G, Ansell JD, Micklem HS, Tjio JH, Cronkite EP. Special proliferative sites are not needed for seeding and proliferation of transduced bone marrow cells in normal syngeneic mice. Proc Natl Acad Sci USA. 1982;79:5085–7.
   PubMed Web of Science ®Google Scholar
• Saxe DF, Boggs SS, Boggs DR. Transplantation of chromosomally marked syngeneic marrow cells into mice not subjected to hematopoietic stem cell depletion. Exp Hematol. 1984;12:277–83.
   Google Scholar
• Stewart FM, Crittenden RB, Lowry PA, Pearson-White S, Quesenberry PJ. Long-term engraftment of normal and post-5-fluorouracil murine marrow in normal nonmyeloablated mice. Blood. 1993;81:2566–71.
   PubMed Web of Science ®Google Scholar
• Ramshaw HS, Crittenden RB, Dooner M, Peters SO, Rao SS, Quesenberry PJ. High levels of engraftment with a single infusion of bone marrow cells into normal unprepared mice [erratum appears in Biol Blood Marrow Transplant. 1996;2:54]. Biol Blood Marrow Transplant. 1995;1:74–80.
   Google Scholar
• Bienzle D, Abrams-Ogg AC, Kruth SA, Ackland-Snow J, Carter RF, Dick JE, . Gene transfer into hematopoietic stem cells: long-term maintenance of in vitro activated progenitors without marrow ablation. Proc Natl Acad Sci USA. 1994;91:350–4.
   PubMed Web of Science ®Google Scholar
• Brecher G, Neben S, Yee M. Bone marrow proliferation after passage through an irradiated host. Prog Clin Biol Res. 1990;352:449–58.
   Google Scholar
• Neff T, Beard BC, Kiem H-P. Review. Survival of the fittest: in vivo selection and stem cell gene therapy. Blood. 2006; 107:1751–60.
   PubMed Web of Science ®Google Scholar
• Trobridge GD, Kiem H-P. Large animal models of hematopoietic stem cell gene therapy. Gene Ther. 2010;17:939–48.
   PubMed Web of Science ®Google Scholar
• Venkataraman GM, Stroup P, Graves SS, Storb R. An improved method for dog leukocyte antigen 88 typing and two new major histocompatibility complex class I alleles, DLA-88*01101 and DLA-88*01201. Tissue Antigens. 2007; 70:53–7.
   Google Scholar